Brief Overview of Current Treatment Landscape for 1L EGFRm NSCLC
Panelists discuss how the treatment landscape for EGFR-mutated lung cancer has evolved with 3 strong options now available, including single-agent osimertinib and 2 combinations: osimertinib plus chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA), with the latter showing significant overall survival (OS) benefits.
Video content above is prompted by the following:
First-Line EGFRm NSCLC Treatment Landscape Overview
Current Treatment Options
The treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC) has evolved significantly, with 3 strong first-line options now available:
- Osimertinib monotherapy:The established standard treatment option
- Osimertinib plus chemotherapy:Supported by the FLAURA2 trial data
- Amivantamab plus lazertinib:Recent combination showing significant survival benefits in the MARIPOSA trial
Recent Advances: MARIPOSA Trial Results
The MARIPOSA trial, a randomized phase 3 study, compared 3 treatment regimens:
- Amivantamab plus lazertinib
- Osimertinib (control arm)
- Lazertinib plus osimertinib
Key Findings:
- Significant OS benefit: HR of 0.75 for amivantamab plus lazertinib compared with osimertinib monotherapy
- Sustained survival advantage: Survival curves separated early and continued to widen over time.
- Potential median OS improvement: Mathematical modeling suggests up to 12 months difference in median survival (though median not yet reached for the treatment arm).
- Impressive landmark data: Progressive improvement in survival difference at 24, 36, and 42 months
The amivantamab plus lazertinib combination represents a novel mechanism targeting both EGFR and cMET receptors, providing a valuable new option for first-line treatment of EGFRm NSCLC.
The trial continues with follow-up for a 5-year landmark analysis, with current survival projections suggesting beyond 4 years of median OS for patients receiving the combination therapy.
